Paul Tudor Jones Arcutis Biotherapeutics, Inc. Transaction History
Tudor Investment Corp Et Al
- $25.1 Billion
- Q4 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 64,334 shares of ARQT stock, worth $837,628. This represents 0.0% of its overall portfolio holdings.
Number of Shares
64,334
Previous 20,964
206.88%
Holding current value
$837,628
Previous $194,000
361.86%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ARQT
# of Institutions
218Shares Held
129MCall Options Held
2.02MPut Options Held
202K-
Jennison Associates LLC12.3MShares$161 Million0.11% of portfolio
-
Suvretta Capital Management, LLC New York, NY11.4MShares$148 Million6.61% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$143 Million2.52% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$114 Million7.34% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$112 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $784M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...